Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India

The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India. Quadrivalent HPV Vaccine is composed of L1 virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.

Inclusion Criteria:

• Healthy Females Age 9 To 15 Years
• Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study
• No Fevers 24 Hours Prior To The First Injection

Exclusion Criteria:

• Participant Had Received A Prior Vaccination With A HPV Vaccine
• Participant Has Allergies To Vaccine Component Including Aluminum And Yeast
• Participant Has (Human Immunodeficiency Virus) HIV Infection
• Participant Is Immunocompromised
• Participant Received Or Plans To Receive Blood-Derived Product Within 6 Months Prior To The First Injection
• Participant Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To The First Injection